Atrial Fibrillation in Primary Aldosteronism

Area of Science:

• Cardiology
• Endocrinology
• Hypertension Research

Background:

• Primary aldosteronism (PA) is the leading cause of secondary hypertension.
• PA patients face higher cardiovascular risks, notably atrial fibrillation (AF), than essential hypertension (EH) patients.
• Excess aldosterone, arterial hypertension, and electrolyte imbalances contribute to AF pathogenesis in PA.

Purpose of the Study:

• To review the complex relationship between primary aldosteronism and atrial fibrillation.
• To highlight current evidence on PA's role in AF development and progression.
• To discuss recent advancements in managing PA concerning AF risk.

Main Methods:

• Review of translational and clinical studies on PA and AF.
• Analysis of registry data and meta-analyses comparing AF prevalence in PA versus EH.
• Examination of outcomes following adrenalectomy and mineralocorticoid receptor antagonist (MRA) treatment.

Main Results:

• PA is linked to increased AF prevalence and risk compared to EH.
• Aldosterone excess contributes to atrial structural and electrical remodeling, promoting AF.
• Adrenalectomy shows promise in reducing new-onset AF (NOAF) risk post-treatment.

Conclusions:

• PA significantly elevates AF risk through multiple mechanisms, including hormonal and structural changes.
• Treatment outcomes for AF in PA patients vary, with adrenalectomy demonstrating potential benefits.
• Further research is needed to optimize medical management of PA to mitigate AF development.